SK Biopharmaceuticals Co Ltd
KRX:326030

Watchlist Manager
SK Biopharmaceuticals Co Ltd Logo
SK Biopharmaceuticals Co Ltd
KRX:326030
Watchlist
Price: 95 400 KRW -2.25% Market Closed
Market Cap: 7.5T KRW
Have any thoughts about
SK Biopharmaceuticals Co Ltd?
Write Note

SK Biopharmaceuticals Co Ltd
Gross Profit

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

SK Biopharmaceuticals Co Ltd
Gross Profit Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Gross Profit CAGR 3Y CAGR 5Y CAGR 10Y
SK Biopharmaceuticals Co Ltd
KRX:326030
Gross Profit
â‚©320.8B
CAGR 3-Years
137%
CAGR 5-Years
211%
CAGR 10-Years
N/A
Yuhan Corp
KRX:000100
Gross Profit
â‚©675.7B
CAGR 3-Years
0%
CAGR 5-Years
10%
CAGR 10-Years
8%
Hanmi Science Co Ltd
KRX:008930
Gross Profit
â‚©242.8B
CAGR 3-Years
23%
CAGR 5-Years
18%
CAGR 10-Years
13%
Hanmi Pharm Co Ltd
KRX:128940
Gross Profit
â‚©875.2B
CAGR 3-Years
15%
CAGR 5-Years
9%
CAGR 10-Years
7%
S
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
Gross Profit
â‚©98.7B
CAGR 3-Years
5%
CAGR 5-Years
-1%
CAGR 10-Years
5%
C
Celltrion Pharm Inc
KOSDAQ:068760
Gross Profit
â‚©114.3B
CAGR 3-Years
1%
CAGR 5-Years
15%
CAGR 10-Years
10%
No Stocks Found

SK Biopharmaceuticals Co Ltd
Glance View

Market Cap
7.5T KRW
Industry
Pharmaceuticals

SK Biopharmaceuticals Co Ltd., a prominent player in the global biopharmaceutical landscape, has carved out a niche in the development of innovative therapies for central nervous system (CNS) disorders. Founded in South Korea as a subsidiary of the SK Group, the company has swiftly gained recognition for its commitment to research and development, particularly in the realm of epilepsy treatments. Its flagship product, Cenobamate, has received approvals in various international markets, establishing a substantial revenue stream and bolstering SK Biopharmaceuticals’ reputation for tackling complex neurological conditions. This focus on underserved medical needs not only highlights the company’s scientific prowess but also reflects its strategic positioning within a growing market projected to expand significantly in the coming years. For investors, SK Biopharmaceuticals embodies a blend of growth potential and stability, driven by a robust pipeline of both established and novel therapies. The company is leveraging cutting-edge technology and extensive clinical research to explore additional indications for its existing products while continuing to develop new candidates. With a strong financial foundation and increasing market penetration, SK Biopharmaceuticals is poised to capitalize on the surging demand for innovative CNS treatments. As the company continues to expand its footprint globally, its commitment to quality, patient-centric approaches, and strategic partnerships will likely enhance shareholder value, making it an attractive consideration for those looking to invest in the biopharmaceutical sector.

Intrinsic Value
42 162.19 KRW
Overvaluation 56%
Intrinsic Value
Price

See Also

What is SK Biopharmaceuticals Co Ltd's Gross Profit?
Gross Profit
320.8B KRW

Based on the financial report for Dec 31, 2023, SK Biopharmaceuticals Co Ltd's Gross Profit amounts to 320.8B KRW.

What is SK Biopharmaceuticals Co Ltd's Gross Profit growth rate?
Gross Profit CAGR 5Y
211%

Over the last year, the Gross Profit growth was 54%. The average annual Gross Profit growth rates for SK Biopharmaceuticals Co Ltd have been 137% over the past three years , 211% over the past five years .

Back to Top